Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Pediatric Acute Lymphoblastic Leukemia (ALL)
Emerging Strategies for Pediatric ALL Management
Category
  • Acute Lymphoblastic Leukemia
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date August 22, 2019
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Pediatric Acute Lymphoblastic Leukemia (ALL)
Emerging Strategies for Pediatric ALL Management
Category
  • Acute Lymphoblastic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: New Therapies for Chronic Lymphocytic Leukemia and a Changing Treatment Paradigm
Join Emily K. Dotson, PharmD, BCOP, from The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute for this webinar in the 2018 NCCN Pharmacy Update Series on the topic New Therapies for Chronic Lymphocytic Leukemia and a Changing Treatment Paradigm.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Management of Adverse Events From Cancer Immunotherapy: Resources for Emergency Medicine Specialists
The goal of this activity is to improve the knowledge, competence, and performance of physicians and other clinicians who provide emergency care for patients with cancer who are experiencing an immune-related adverse event from immune checkpoint inhibitor therapy.
Category
Format
  • Recorded Webcast
Credits
  • AMA PRA Category 1 Credit™
  • Participation
NCCN Oncology Case Manager and Medical Director Program: Updates in the Treatment of HER-2 Positive Breast Cancer
It is important for clinicians to be aware of the updated criteria to appropriately select patients who are sensitive to HER2-targeted agents; to stay up-to-date with evolving treatment strategies; to understand how to choose optimal treatment based on patient preference, toxicities, and drug availability; and to effectively evaluate patients during therapies and manage any therapy-related adverse effects.
Category
  • Breast Cancer
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date October 10, 2019
NCCN Oncology Case Manager and Medical Director Program: Updates in the Treatment of Follicular Lymphoma and Diffuse Large B-Cell Lymphomas
Case managers and medical directors are challenged to maintain a high awareness of the recent therapeutic advances in the management of FL and DLBCL in order to develop an efficient coordinated treatment approach that incorporates novel therapies in the appropriate patient population.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date October 25, 2019
NCCN Oncology Case Manager and Medical Director Program: Managing Cancer Pain in the U.S. Opioid Crisis
To ensure safe access to opioid pain medications for patients with cancer, all members of the healthcare team need to understand the benefits of opioids, how to navigate the federal and state programs regulating opioid use, and how to develop strategies to prevent opioid misuse.
Category
  • Pain
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date December 10, 2019
NCCN Oncology Case Manager and Medical Director Program: New Treatments for Metastatic Lung Cancer
The new combination immunotherapy + chemotherapy regimens represent a major change in systemic therapy for patients with metastatic NSCLC. Case managers and other health care providers have less experience with these new immunotherapy + chemotherapy regimens or the newer targeted therapies that have different mechanisms of action and side effects than traditional cytotoxic chemotherapy regimens.
Category
  • Lung Cancers
Format
  • Live Webinar
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Event date December 19, 2019

Pages